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Drug Discovery: Is it Relevant to
Complementary and Alternative
Medicine (CAM)?
This editorial is related to two papers in volume 1 issue 2 of
eCAM and to others concerned with molecules derived from
terrestrial and marine species (1–15). These papers focus on
natural products, especially those derived from the sea.
Therefore, it is appropriate to apply the contributions of these
papers, since they can offer a different perspective. It is,
indeed, a matter of great coincidence that these papers are
being published at a time when eCAM is making extensive
efforts to highlight this subject, which occupies an important
place in biomedicine and has enormous potential. This situa-
tion in which the focus, at least of publications, is on animal
products, is in marked contrast to that of botanicals and
herbals—qua plant-derived molecules, the available literature
on which may be considered immense and sometimes focused
in highly specialized journals.
A recent issue of Science offers a veritable cornucopia of
evidence concerned with new drugs, and it begins with an
editorial entitled ‘Drug Discovery’ by Donald Kennedy 
Editor-in-Chief (16). This is followed by an introduction titled
‘Rethinking Drug Discovery (17) and a news essay, ‘Surviving
the Blockbuster Syndrome; Orphan Drugs of the Future’ (18).
Five reviews and viewpoints examine various aspects of molec-
ular biology, organic chemistry and drug delivery systems
(19–23).
If one explores the enormous wealth in this issue of Science
in science’s next wave (www.nextwave.org), at least five
presentations offer enormous potential for application
(Bioprospecting beginning with ‘The Sweet Side of Venom
and Practicing’ (24–28). This sojourn into the world of drug
discovery is, in my opinion, an area pertinent to complemen-
tary and alternative medicine (CAM). It is not remote but is
closely related, relevant and highly visible, not to mention
that it has rapidly increasing potential for wider distribution
and understanding. This appears almost inevitable with the
practice of western medicine shifting somewhat or, at least,
bridging the divide between western and eastern medicine
through the intervention of CAM. After all, many of these
claims of healing have deep and everlasting recorded roots in
the ancient world, most notably throughout Asia. The chal-
lenge will be to subject certain claims to the rigors of science
and demand that conclusions be evidence-based (12).
Otherwise, CAM will be unable to withstand the criticism of
biologists and, sometimes, that of educated and skeptical
public.
Historical Approaches to Antibiotics—A
Template for CAM?
There is a current trend of discovery and applications of bioac-
tive agents from natural sources. According to Grabley and
Thiericke (29), natural products account for 30% of interna-
tional drug sales. Although recombinant proteins and peptides
have been accounting for an increasing amount of sales, the
superiority of low-molecular mass compounds in human dis-
ease therapy remains undisputed, mainly due to more favor-
able compliance and bioavailability. To meet the demand for
the thousands of test samples that must be submitted for high-
throughput screening (HTS), it is essential to successfully
compete with the rigors of combinatorial chemistry by devel-
oping new strategies in natural product chemistry. HTS
enables the testing of a large number of samples. Therefore,
new concepts that can generate large collection of compounds
that possess improved structural diversity are desirable.
In the historical context and as a brief background, the
discovery of antibiotics clearly ushered in a new approach for
treating patients. It was entirely fortuitous—a byproduct of
serendipity, a circumstance that scientists yearn for but from
which they often do not benefit. In many respects, a template
for CAM was being formed. Unlike this valuable discovery,
and the currently emerging paradigm, the world of natural
products has been awaiting more beneficial exploitation for
several millennia. After all, what were people using as remedies
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derivative work this must be clearly indicated.long before Fleming’s discovery of penicillin? In 1948, Japan
was the third country, after the United States and the United
Kingdom, to become self-sufficient in manufacturing penicillin
(30). In addition to penicillin, there was an enormous amount
of national exploratory research focusing on anti-infective,
anti-cancer and agricultural antibiotics. Here is a summary, a
brief chronology of discoveries. The first few antibiotics from
Japan were colistin (1950), mitomycin C (1955), kanamycin
(1957), bleomycin (1965), cefazolin (1969), amikacin (1972),
piperacillin (1976), norfloxacin (1977), cefoperazone (1978),
ofloxacin (1980), clarithromycin (1984), meropenem (1987),
etc. Noteworthy antibiotic research on bioactive microbial
products led to the discovery of agents beneficial to improving
the human quality of life (QOL), e.g., pravastatin for hyperlipi-
demia and tacrolimus for atopic diseases. As an example
among other nations, Japan will continue to maintain a high
level of activity in exploratory research on beneficial
chemotherapeutic agents during this century. The Japanese
Society of Chemotherapy (JSC), established in 1953, has
played a central role in evaluating novel agents including those
introduced from other countries. The JSC is active in establish-
ing guidelines for chemotherapy and in educating clinical
scientists as well as evaluating chemotherapeutic agents both
fundamentally and clinically.
The Oceans are a Rich Source of Natural
Products that are Potential Medicinals—
Natural Product Formulations Available in
Europe for Psychotropic Indications
During the mid 20th century, the development of medical
treatments for human disease was intimately connected with a
variety of products derived largely from the plant kingdom
(31). Despite recent advances in utilizing chemically synthetic
approaches to drug design and sophisticated structure-activity
analyses, there continues to exist a great requirement in medi-
cine for novel compounds with unique action mechanisms.
While several thousands of structural analogs have been syn-
thesized and tested, numerous gaps remain in the therapeutic
armamentarium for psychiatric illnesses. A majority of the
new drugs marketed for psychotherapeutic indications have
only served as incremental improvements on existing medica-
tions. Significant discoveries have resulted primarily from ana-
lyzing natural products. Several valuable drugs have been
isolated from plant and animal sources; these include aspirin,
morphine, reserpine (the first antipsychotic), almost all anti-
biotics, digitalis, and anti-cancer agents such as vincristine,
vinblastine, and Taxol.
Drugs from the Sea: Harvesting the Results
of Aeons of Chemical Evolution
According to Wallace (32), despite recent developments in
combinatorial chemistry that can rapidly generate thousands of
new chemicals, the pharmaceutical industry still relies heavily
on a staggering array of undiscovered possibilities from the
natural environment. These could lead to the discovery of
novel compounds that will surely extend the boundaries of our
chemical research efforts. The terrestrial environment has been
mined for compounds for many years, with great success.
Currently, promising compounds are being tapped from the
world’s oceans. Many of these chemicals are structurally com-
plex, which challenges modern organic chemists with unlim-
ited approaches to mimic the synthetic versatility of nature. In
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Table 1. Marine compounds under evaluation as potential drugs
Compound Source Activity Status
Bryostatin I Bryozoan, Bugula neritina Anti-cancer Phase II clinical trials
Ecteinascidin 743 Tunicate, Ecteinascidia turbinate Anti-cancer: lung, breast and  Phase I clinical trials
ovarian cancer, melanoma
Didemnin B (Aplidine) Tunicate, Trididemnum solidum Anti-cancer: central nervous system  Phase II clinical trials
cancers, non-Hodgkin’s lymphoma
Dolastatin 10 Opisthobranch mollusc, Dolabella  Anti-cancer Phase I clinical trials
auricularia
Halomon Alga, Portieria hommannii Anti-cancer Advanced pre-clinical studies
Halichondrin B Marin sponge, Halichondria okadai Anti-cancer Advanced pre-clinical studies
Discodermolide Marine sponge, Discodermia dissoluta Anti-cancer: immunosuppressant Advanced pre-clinical studies
Jaspalkilonide (NCI) Marine sponge, Jaspis spp. or  Anti-cancer: antifungal Pre-clinical studies
Dorypleres splendens
Manaloide Marine sponge, Luffariella variabilis Pharmacophore lead for numerous  —
anti-inflammatory compounds
Dehydrodidemnin B Tunicate, Aplidium albicans Anti-cancer: prostate, lung, colorectal Pre-clinical  studies
and central nervous system cancers
Kahalalide F Mollusc, Elysia rubefescens Anti-cancer: colon and prostate cancer Pre-clinical studies
Mycaperoxide B Marine sponge, Mycale spp. Anti-cancer: ovarian and lung cancer Pre-clinical studies
Cyptophycin Blue-green alga, Nostoc spp. Anti-cancer Advanced pre-clinical studies
Reprinted from Molecular Medicine Today, 3, Wallace R. W., Drugs from the sea: harvesting the results of aeons of chemical evoluation, 291–299, 1997, with
permission from Elsevier.the future, these marine compounds are likely to yield entirely
new classes of drugs which would be a valuable contribution
to our ability to treat human disease. We are in need of such
overtures, discoveries and innovations in the face of rising
medical costs and the fact that a fraction of the general public
(at least in the US) is underinsured and often disgruntled with
modern-day, western medical practice. As we visualize a
vaguely relevant situation of coexistence, a rather simple ana-
logy is perhaps appropriate. Street markets are now offering
complementary and alternative sources to the supermarket
with its chilled atmosphere and speedy and efficient service.
Perhaps we wish for something that has a long past and that
offers, in many instances, equivalent or better service and
assistance. CAM could possibly represent our street markets,
whereas western medicine could be viewed as a super market.
Clearly, this brief sojourn reveals that medicine benefits
immensely from the rich pharmacopoeia-products of our ter-
restrial and aquatic environments—both plants and animals.
Although most medicines are derived from terrestrial plants
and animals, ecologists estimate the number of species in the
marine environment to be 0.5–10 million. Most of these are
still waiting to be discovered, opening neither a Pandora’s box
nor a can of worms but an unfathomable array of newer cures.
Several questions may be posed in this new era of explo-
ration: Why marine organisms such as invertebrates? (32).
Can problems related to synthesis and supply of marine natu-
ral products of pharmacological interest be resolved? So far,
most marine secondary products are cellular toxins. What are
the limits of marine biodiversity and how rapidly is this biodi-
versity being lost? Is it possible to provide a rational basis for
discovering useful marine natural products by understanding
the ecological interactions of organisms that compete with
each other for food and space? What are the evolutionary con-
nections between secondary metabolites from the marine
world and the signaling pathways within our own bodies?
Clearly, the papers included in eCAM provide some of the
answers.
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